Welcome to our dedicated page for Merck & Co. news (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & Co. stock.
Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, is a renowned American multinational pharmaceutical company headquartered in Rahway, New Jersey. Originally the American arm of Germany's Merck Group founded in 1668, Merck has established itself as a global leader in pharmaceuticals and vaccines.
Merck's core business is the development and manufacturing of medications and vaccines spanning several therapeutic areas such as cardiometabolic diseases, cancer, and infections. The company's immuno-oncology platform, particularly strong in cancer treatment, is a significant revenue driver. The firm’s oncology portfolio includes groundbreaking immunotherapies like KEYTRUDA, designed to treat melanoma and other cancers. KEYTRUDA, in combination with other therapies, has shown promising results in reducing cancer recurrence and improving survival rates.
Merck also boasts a robust vaccine business, offering vaccines for pediatric diseases and human papillomavirus (HPV). Their commitment to public health extends to Merck for Mothers, an initiative aimed at improving maternal health globally. In 2024, Merck surpassed its goal early by reaching over 30 million women with programs promoting safe, high-quality maternal care.
The company's animal health division is another sector of its diverse operations, providing solutions to improve animal health and productivity.
From a geographical perspective, nearly half of Merck's sales are generated in the United States. Financially, Merck maintains a solid position with ongoing investments in research and development to fuel innovation. The company is actively engaged in numerous partnerships and collaborative research initiatives to accelerate the development of new therapies.
Merck’s mission is rooted in scientific excellence and an unwavering commitment to improving lives. The company continues to invest in leading-edge research, with over 2,250 ongoing clinical trials, including more than 1,600 trials evaluating combination regimens. This dedication underpins Merck's strategy to address complex health challenges and advance global health.
Merck (NYSE: MRK) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of KEYTRUDA combined with chemotherapy for treating persistent, recurrent, or metastatic cervical cancer in adults with PD-L1 expressing tumors (CPS ≥1). This recommendation follows the Phase 3 KEYNOTE-826 trial, which showed significant improvements in overall survival (HR=0.64) and progression-free survival (HR=0.62), with a 68% objective response rate compared to 50% for chemotherapy alone. A final decision from the European Commission is anticipated in Q2 2022.
Merck (NYSE: MRK) announced the retirement of Dr. Roy D. Baynes, Chief Medical Officer, effective July, with Dr. Eliav Barr succeeding him on April 1, 2022. Dr. Baynes has significantly contributed to Merck's oncology leadership, notably through the development of KEYTRUDA. Under Dr. Barr, who has over two decades with Merck, the company aims to continue advancements in clinical development, particularly in oncology and vaccines. This leadership transition aims to ensure ongoing growth and innovation in Merck’s pipeline.
Merck (NYSE: MRK) presented findings at the 48th Annual European Society for Blood and Marrow Transplantation Meeting, revealing that PREVYMIS™ (letermovir) significantly lowers the risk of cytomegalovirus (CMV) reactivation in CMV-seropositive patients undergoing allogeneic hematopoietic cell transplantation. The meta-analysis of 48 studies showed a 87% reduction in CMV reactivation and a 91% reduction in clinically significant CMV infections at 100 days. Results were consistent at 200 days, reinforcing PREVYMIS as a critical prophylactic treatment in this high-risk patient population.
Merck (NYSE: MRK) has received FDA approval for KEYTRUDA as a treatment for patients with advanced endometrial carcinoma that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). The approval is based on data from the KEYNOTE-158 trial, which demonstrated a 46% objective response rate (ORR) with a 12% complete response and 33% partial response among patients treated with KEYTRUDA. This marks KEYTRUDA's fourth indication in gynecologic oncology, emphasizing its potential in addressing advanced endometrial cancer.
Merck (NYSE: MRK) announced pivotal results from the Phase 3 KEYNOTE-091 trial for the adjuvant treatment of non-small cell lung cancer (NSCLC). The study showed that KEYTRUDA significantly improved disease-free survival (DFS) by 24% compared to placebo, with a median DFS of 53.6 months versus 42.0 months. These data will be shared with regulatory authorities globally. Despite positive outcomes, the study noted that improvement in DFS for high PD-L1 expression patients was not statistically significant. The safety profile was consistent with previous studies.
Merck (NYSE: MRK) and AstraZeneca have released positive data from the Phase 3 OlympiA trial, highlighting LYNPARZA's effectiveness as an adjuvant treatment for patients with germline BRCA-mutated early breast cancer. The trial demonstrated a 32% reduction in the risk of death (HR=0.68) compared to placebo, with three-year survival rates of 92.8% for LYNPARZA versus 89.1% for placebo. These findings will be showcased at the European Society for Medical Oncology Virtual Plenary, marking a significant advancement for early breast cancer treatment.
Merck (NYSE: MRK) announced the discontinuation of the Phase 3 KEYLYNK-010 trial, which studied KEYTRUDA with LYNPARZA for metastatic castration-resistant prostate cancer. The independent Data Monitoring Committee recommended stopping the trial after an interim analysis revealed no overall survival benefit compared to control treatments. The combination also showed a higher incidence of serious adverse events. Despite this setback, Merck continues to explore other KEYTRUDA combinations across various cancers, maintaining a strong clinical development program.
Merck (NYSE: MRK) announced that LYNPARZA received FDA approval as the first targeted adjuvant therapy for patients with BRCA-mutated, HER2-negative high-risk early breast cancer. This is a significant milestone as LYNPARZA demonstrated a 42% reduction in the risk of invasive breast cancer recurrence and a 32% reduction in the risk of death compared to placebo, based on the Phase 3 OlympiA trial. Merck will make a $175 million payment to AstraZeneca under their collaboration agreement following this approval, potentially enhancing the market position of LYNPARZA.
Merck (NYSE: MRK) will host a virtual investor event on April 5, 2022, at 10:00am ET, after the American College of Cardiology Scientific Session 2022. The event will provide insights into Merck’s extensive cardiovascular portfolio and pipeline. Cardiovascular disease remains a significant global health issue, claiming approximately 18 million lives annually. Merck highlights its commitment to innovation and research in this field, aiming to improve patient outcomes. For more details, visit Merck's investor relations website.
Merck (NYSE: MRK) announced positive results from the Phase 3 KEYNOTE-716 trial, which evaluated KEYTRUDA as adjuvant treatment for patients with resected stage IIB and IIC melanoma. The trial met its key secondary endpoint of distant metastasis-free survival (DMFS), showing a statistically significant improvement compared to placebo. Additionally, KEYTRUDA demonstrated improved recurrence-free survival (RFS) at previous analyses. No new safety concerns were noted, reinforcing its efficacy as an adjuvant therapy. Full results will be presented at an upcoming medical meeting.
FAQ
What is the current stock price of Merck & Co. (MRK)?
What is the market cap of Merck & Co. (MRK)?
What are the main therapeutic areas Merck focuses on?
What is Merck for Mothers?
What are some of Merck’s key products in oncology?
How significant is Merck’s vaccine business?
Where is Merck headquartered?
What percentage of Merck’s sales comes from the United States?
What is Merck's approach to research and development?
What recent achievements has Merck announced?
Does Merck collaborate with other companies for research?
What is the historical origin of Merck & Co., Inc.?
